<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682522</url>
  </required_header>
  <id_info>
    <org_study_id>20.1054</org_study_id>
    <nct_id>NCT04682522</nct_id>
  </id_info>
  <brief_title>Flagyl Microbiome in Crohn's Disease</brief_title>
  <official_title>Does the Microbiome Change With Flagyl Treatment After Ileocolic Resection for Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the types of bacteria in the colon before and after colon resection&#xD;
      surgery. The investigator will also compare standard post-operative antibiotic treatment to&#xD;
      flagyl (metronidazole) treatment post-operatively to see if giving the antibiotic, decreases&#xD;
      the incidence of return of Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who are scheduled for colon resection for Crohn's disease will be invited to&#xD;
      take part in this randomized study. Participants will be randomized 1:1 to either&#xD;
      Metronidazole 250 mg three times a day, starting after surgery, for three months, or the&#xD;
      local usual standard of care after surgery, which may be a different antibiotic prescribed by&#xD;
      the physician.&#xD;
&#xD;
      Participants will also provide a stool sample at the following time points: prior to surgery,&#xD;
      the day of discharge, at their follow-up appointment (usually about two weeks after surgery),&#xD;
      three months, and six months.&#xD;
&#xD;
      Participants will also be followed to determine their clinical outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1 study groups</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bacteria in the gut</measure>
    <time_frame>six months</time_frame>
    <description>Any change in the types of bacteria in the gut during the study period. This will be done by doing genetic analysis of differences in stool over time.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole 250 mg three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard post-operative care, which may or may not include post-operative antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Oral</intervention_name>
    <description>250 mg Three times a day</description>
    <arm_group_label>Metronidazole</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20-80 years old who is deemed an acceptable surgical candidate for ileocolic&#xD;
             resection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any patients that are dependent on total parenteral nutrition and unable to tolerate&#xD;
             oral intake&#xD;
&#xD;
          -  patients who will undergo resection but will have an ileostomy created&#xD;
&#xD;
          -  patients on maintenance antibiotics for their disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Kavalukas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Kavalukas, MD</last_name>
    <phone>502-583-8303</phone>
    <email>sandy.kavalukas@louisville.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Surgical Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Kavalukas, MD</last_name>
      <phone>502-583-8303</phone>
      <email>sandy.kavalukas@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura S Trachtenberg</last_name>
      <phone>15029051365</phone>
      <email>lstrac01@louisville.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>sandykava</investigator_full_name>
    <investigator_title>Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

